Hugel, Inc. (KOSDAQ:145020)
South Korea · Delayed Price · Currency is KRW 252,500
-10,500 (-3.99%)
Apr 30, 2026, 3:30 PM KST
Hugel Revenue
In the year 2025, Hugel had annual revenue of 425.11B KRW with 13.96% growth. Hugel had revenue of 119.13B in the quarter ending December 31, 2025, with 21.30% growth.
Revenue
425.11B
Revenue Growth
+13.96%
P/S Ratio
6.42
Revenue / Employee
715.67M
Employees
594
Market Cap
2.73T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 425.11B | 52.06B | 13.96% |
| Dec 31, 2024 | 373.05B | 53.35B | 16.69% |
| Dec 31, 2023 | 319.70B | 38.02B | 13.50% |
| Dec 31, 2022 | 281.68B | 49.82B | 21.49% |
| Dec 31, 2021 | 231.86B | 20.82B | 9.87% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chabiotech | 1.27T |
| SK bioscience | 651.37B |
| PharmaResearch | 536.29B |
| LigaChem Biosciences | 141.55B |
| MEDIPOST | 73.66B |
| Pharmicell | 23.94B |
| OliX Pharmaceuticals | 14.67B |
| Voronoi | 7.51B |